Claims

1. An acid addition salt of l-(5-(2,4-difluorophenyl)-l-((3-fluorophenyl)sulfonyl)-4-methoxy-lH-pyrrol-3-yl)-N-methylmethanamine wherein the acid is succinic acid, or tartaric acid.

2. A method for preparing an acid addition salt of l-(5-(2,4-difluorophenyl)-l-((3-fluorophenyl)sulfonyl)-4-methoxy-lH-pyrrol-3-yl)-N-methylmethanamine of claim 1 comprising the steps of:

1) dissolving l-(5-(2,4-difluorophenyl)-l-((3-fluorophenyl)sulfonyl)-4-methoxy-lH-pyrrol-3-yl)-N-methylmethanamine and an acid, respectively, in an organic solvent to prepare a l-(5-(2,4-difluorophenyl)-l-((3-fluorophenyl)sulfonyl)-4-methoxy-lH-pyrrol-3-yl)-N-methylmethanamine solution and an acid solution; and

2) mixing the l-(5-(2,4-difluorophenyl)-l-((3-fluorophenyl)sulfonyl)-4-methoxy-lH-pyrrol-3-yl)-N-methylmethanamine solution and the acid solution and then stirring the mixed solutions.

3. The method for preparing an acid addition salt of l-(5-(2,4-difluorophenyl)-l-((3-fluorophenyl)sulfonyl)-4-methoxy-1 H-pyrrol-3 -yl)-N-methylmethanamine of claim 2,

wherein the acid is succinic acid, or tartaric acid.

4. The method for preparing an acid addition salt of l-(5-(2,4-difluorophenyl)-l-((3-fluorophenyl)sulfonyl)-4-methoxy-l H-pyrrol-3-yl)-N-methyl methanamine of claim 2,

wherein the organic solvent is one or more selected from the group consisting of n-hexane, ethyl acetate, butyl acetate, acetonitrile, chloroform, diethyl ether, acetone, methanol and ethanol.

5. A pharmaceutical composition for use in the prevention and treatment of gastrointestinal injury due to gastrointestinal tract ulcer, gastritis, reflux esophagitis, or Helicobacter pylori (*H. pylori*), comprising an acid addition salt of l-(5-(2,4-difluorophenyl)-l-((3-fluorophenyl)sulfonyl)-4-methoxy-lH-pyrrol-3-yl)-N-methylmethanamine of claim 1.